Boehringer Ingelheim Corporation Release: Cost Effectiveness and Clinical Efficacy of Pradaxa® (Dabigatran Etexilate) Versus Rivaroxaban Analysed  
8/24/2012 10:01:38 AM

INGELHEIM, Germany--(BUSINESS WIRE)-- In the absence of a head-to-head study, a comprehensive analysis published in Thrombosis and Hemostasis,1 looks into the efficacy and cost-effectiveness of Pradaxa® for stroke prevention in patients with non-valvular atrial fibrillation in an indirect comparison to rivaroxaban. The analysis, based on two large scale trials including more than 32.000 patients combined, suggests that patients treated with Pradaxa® may have lower rates of ischaemic stroke and intracranial haemorrhage (ICH), and also accumulate lower costs from acute care and long-term follow-up over their lifetime than patients treated with rivaroxaban.1